The UK-US agreement on zero tariffs and pricing reforms positions the UK as a global hub for new medicines. A key element of the deal is confirmation that UK drug exports to the US will face a preferential tariff rate of 0% for at least three years. These reforms promote duty-free export of finished pharmaceutical products. The agreement strengthens the position of the UK in the international drug market. Preferential rates apply exclusively to drugs bound for the US. The move is part of broader price reforms between the two countries.